Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes

IDrugs

Volumn 12, Issue 5, 2009, Pages 309-317

  Doggrell, S A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; ANTITHROMBOCYTIC AGENT; AR C124910XX; AZ 11703072; AZ 11931283; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BRILINTA; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; DRUG METABOLITE; EPTIFIBATIDE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GELATINASE B; OMEPRAZOLE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIDOXAL 5 PHOSPHATE; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLEEDING TIME; CHEMICAL REACTION; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE PAUSE; HEART VENTRICLE TACHYCARDIA; HEMATURIA; HUMAN; HYPOTENSION; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; PATENT; QT PROLONGATION; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

ACUTE CORONARY SYNDROME; ADENOSINE; ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; PLATELET AGGREGATION INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS; TREATMENT OUTCOME;

EID: 67649360021     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. AstraZeneca's sales rise 10% in 2005 AstraZeneca plc PRESS RELEASE 2006 February 02
2. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G EUR HEART J 2006 27 9 1038-1047
3. 12 antagonists. van Giezen JJJ, Humphries RG SEMIN THROMB HEMOST 2005 31 2 195-204
4. 12 receptor. Ding ZG, Kim S, Kunapuli SP MOL PHARMACOL 2006 69 1 338-345
5. Dyspnoea after antiplatelet agents: The AZD6140 controversy. Serenbruany VL, Stebbing J, Atar D INT J Clin PRACT 2007 61 3 529-533
6. 12 receptor antagonist AZD6140 are similar for healthy Japanese and Caucasian volunteers. Ruckle JL, Winter HR, Garber S, Mitchell PD, Yoshioka T, Butler KA CLIN PHARMACOL THER 2007 81 Suppl 1 S49
7. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of the reversible oral ADP receptor antagonist AZD6140. Peters G, Butler K, Winter HR, Mitchell PD EUR HEART J 2006 27 Suppl 1 758
8. Comparison of antiplatelet and antithrombotic effects of prasugrel and AZD6140. Ogawa T, Isobe C, Kakusaka F, Yokouchi Y, Niitsu Y, Jakubowski JA, Sugidachi A, Asai F CONGRESS INT SOC THROMB HAEMOSTASIS 2007 XXI July 10 Abs P-T-645
9. 12 antagonist AZD6140 compared with the thienopyridine, clopidogrel, in both a rat and dog model of combined thrombosis and hemostasis. Björkman JA, van Giezen JJJ, Zachrisson H CONGRESS INT SOC THROMB HAEMOSTASIS 2007 XXI July 9 Abs P-M-279
10. 12 by AZD6140 reduces thrombus formation and proagulation activity on collagen and atherosclerotic plaques. Kuipers MJE, Cosemans JMEM, van der Meijden REJ, Feijge MAH, Heemskerk JWM J THROMB HAEMOST 2007 5 Suppl 2 P-W-275
11. AstraZeneca Development Pipeline 26 July 2007 AstraZeneca plc COMPANY WORLD WIDE WEB SITE 2007 July 26
12. 12 receptor antagonist for the prevention of thrombosis. Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG, Hunt SF et al BIOORG MED CHEM LETT 2007 17 21 6013-6018.
13. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion. Bjorkman JA, Kirk I, van Giezen JJ AM HEART ASSOC SCIENTIFIC SESSIONS 2007 November 04 Abs 245
14. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF J AM COLL CARDIOL 2007 50 19 1844-1851
15. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndrome. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande Peer CCP J AM COLL CARDIOL 2007 50 19 1852-1856
16. Annual Report and Form 20-F 2007 - AstraZeneca AstraZeneca plc ANNUAL REPORT 2008 March 06
17. 12 receptor expressed on CHO-K1 cells. van Giezen JJ, Berntsson PS, Wissing BM ARTERIOSCLER THROMB VASC BIOL 2008 28 6 E72
18. 12 receptor expressed on CHO-K1 cells receptor at a site distinct form the ADP binding site but antagonizes ADP-induced signaling. van Giezen JJ, Nilsson LB ARTERIOSCLER THROMB VASC BIOL 2008 28 6 e104-e105
19. 12 antagonist AZD6140 compared to clopidogrel and AZ11703072, a chemical compound indistinguishable from prasugrel, in both a rat and a dog model of combined thrombosis and hemostasis. van Diezen JJ, Zachrisson H, Bjorkman JA ARTERIOSCLER THROMB VASC BIOL 2008 28 6 e140
20. 12 receptor vs AZ11702105, a chemical compound indistinguishable from the active metabolite of prasugrel, and is a more potent inhibitor of ADP-induced platelet aggregration. van Giezen JJ, Berntsson PS ARTERIOSCLER THROMB VASC BIOL 2008 28 6 e139-e140
21. 12 receptor antagonist, administered with aspirin. Butler K, Winter H, Mitchell P, Fox J J CLIN PHARMACOL 2007 47 9 1204
22. 2Q and half year results 2008. AstraZeneca plc COMPANY PRESENTATION 2008 July 31
23. FDA continues to review prasugrel new drug application. Daiichi Sankyo Co Ltd, Eli Lilly & Co PRESS RELEASE 2008 September 26
24. Prasugrel receives unanimous approval recommendation from FDA advisory committee. Eli Lilly & Co; Daiichi Sankyo Co Ltd PRESS RELEASE 2009 February 03
25. European Commission approves EFIENT(R) (prasugrel) for patients with acute coronary syndrome undergoing PCI. Eli Lilly & Co; Daiichi Sankyo Co Ltd PRESS RELEASE 2009 February 23
26. 12 antagonism: Promises and challenges. Michelson AD ARTERIOSCLER THROMB VASC BIOL 2008 28 3 s33-s38
27. Dipyridamole, cerebrovascular disease, and the vasculature. Chakrabarti S Freedmand JE VASCULAR PHARMACOLOGY 2008 48 4-6 143-149
28. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Cattaneo M ARTERIOSCLER THROMB VASC BIOL 2004 24 1980-1987
29. 12 receptor antagonist, in healthy subjects. Butler K, Mitchell PD, Teng R CLIN PHARMACOL THER 2009 85 Suppl 1 S20
30. Single doses of AZD6140 900 mg do not prolong the QT interval in healthy subjects. Butler K, Wei C, Teng R PHARMACOL THER 2009 85 Suppl 1 S20
31. ADP receptors: Inhibitory strategies for antiplatelet therapy. Cattaneo M TIMELY TOP MED CARDIOVASC DISEASE 2006 10 E22
32. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Storey RF, Oldroyd KG, Wilcox RG THROMB HAEMOST 2001 85 3 401-407
33. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomized controlled trial. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM LANCET 2009 373 723-731
34. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusus S CIRCULATION 2003 108 14 1682-1687
35. Clinical aspects of platelet inhibitors and thrombus formation. Meadows TA, Bhatt DL CIRC RES 2007 100 1261-1275
36. Effect of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PRI-CURE study. Mehta S, Yusuf S, Peters R, Bertrand M, Lewis B LANCET 2001 358 527-533
37. Secondary prevention of stroke and transient ischemic attack: Is more platelet inhibition the answer? Liao JK CIRCULATION 2007 115 912 1615-1621
38. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. Bhatt DL AM J CARDIOL 103 3 Suppl 11A-19A
39. Platelet ADP-receptor antagonists for cardiovascular disease: Past, present and future. Raju NC, Eikelboom JW, Hirsh J NAT CLIN PRACT CARDIOVASC MED 2008 5 12 766-780
40. Ticlopidine and clopidogrel. Quinn MJ, Fitzgerald DJ CIRCULATION 1999 100 15 1667-1672
41. The broken balance in aspirin hypersensitivity. Szczeklik A, Sanak M EUR J PHARMACOL 2006 533 1-3 145-155
42. 12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Högberg C, Svensson H, Gustafsson R, Eyjolfsson A, Erlinge D INT J CARDIOL 2009 January 26 [Epub ahead of print]
43. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model. Dai J, Louedec L, Philippe M, Michel JB, Houard X J VASC SURG 2009 49 3 719-727
44. Daichii and Lilly launch prasugrel in UK for ACS-PCI Daiichi Sankyo Co Ltd PRESS RELEASE 2009 April 08